Developments in hepatitis C therapy during 2000 - 2002

F. Fred Poordad, Tram Tran, Paul Martin

Research output: Contribution to journalReview article

7 Scopus citations

Abstract

Hepatitis C virus (HCV) is a human hepatotropic virus with an estimated worldwide prevalence of 170 million cases, including ∼ 4 million cases in the US. It is a major cause of liver disease and is the most common indication for liver transplantation in the US. The majority of infected individuals are eligible for therapy. Since it is difficult to predict who will have progressive disease, those with significant inflammation or fibrosis on histologic examination of liver biopsy are generally offered treatment. The following chapter is an overview of the patent literature during 2000 - mid-2002, and discusses the potential of various treatment modalities for HCV.

Original languageEnglish (US)
Pages (from-to)9-25
Number of pages17
JournalExpert Opinion on Emerging Drugs
Volume8
Issue number1
DOIs
StatePublished - May 1 2003
Externally publishedYes

Keywords

  • Antisense oligonucleotide
  • Helicase inhibitors
  • Hepatitis C virus (HCV)
  • Immunomodulators
  • Nucleoside analogue
  • Pegylated interferon
  • Protease inhibitors
  • Ribozymes

ASJC Scopus subject areas

  • Pharmacology

Fingerprint Dive into the research topics of 'Developments in hepatitis C therapy during 2000 - 2002'. Together they form a unique fingerprint.

  • Cite this